Building Trust in COVID-19 Vaccines and Beyond Through Authentic Community Investment

/in

Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine

/in ,

Sadoff, Jerald, Georgi Shukarev, Dirk Heerwegh, Carla Truyers, Anne M. De Groot, Jeroen Stoop, Sarah Tete, Wim VanDamme, Isabel Leroux-Roels, Pieter-Jan Berghmans, Murray Kimmel, Pierre Van Damme, Jan De Hoon, William Smith, Kathryn Stephenson, Stephen De Rosa, Kristen Cohen, Juliana McElrath, Emmanuel Cormier, Gert Scheper, Dan Barouch, Jenny Hendriks, Frank Struyf, Macaya Douoguih, Johan Van Hoof, and Henneke Schuitemaker. “Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine.” The New England Journal of Medicine (2021). Print.

Compassionate Use of Remdesivir in Pregnant Women with Severe Covid-19

/in ,

Burwick RM, Yawetz S, Stephenson KE, Collier AY, Sen P, Blackburn BG, Kojic EM, Hirshberg A, Suarez JF, Sobieszczyk ME, Marks KM, Mazur S, Big C, Manuel O, Morlin G, Rose SJ, Naqvi M, Goldfarb IT, DeZure A, Telep L, Tan SK, Zhao Y, Hahambis T, Hindman J, Chokkalingam AP, Carter C, Das M, Osinusi AO, Brainard DM, Varughese TA, Kovalenko O, Sims MD, Desai S, Swamy G, Sheffield JS, Zash R, Short WR. Compassionate Use of Remdesivir in Pregnant Women with Severe Covid-19. Clin Infect Dis. 2020 Oct 8:ciaa1466. doi: 10.1093/cid/ciaa1466. Epub ahead of print. PMID: 33031500; PMCID: PMC7797739.

Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention

/in

Stephenson KE, Wagh K, Korber B, Barouch DH. Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention. Annu Rev Immunol. 2020;38:673‐703. doi:10.1146/annurev-immunol-080219-023629

Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor

/in

Dussupt V, Sankhala RS, Gromowski GD, et al. Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor. Nat Med. 2020;26(2):228‐235. doi:10.1038/s41591-019-0746-2

Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial

/in , ,

Stephenson KE, Wegmann F, Tomaka F, et al. Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22) [published online ahead of print, 2020 Feb 17] [published correction appears in Lancet HIV. 2020 Feb 28;:]. Lancet HIV. 2020;S2352-3018(20)30001-1. doi:10.1016/S2352-3018(20)30001-1

HIV-1 neutralizing antibody signatures and application to epitope-targeted vaccine design.

/in ,

Bricault CA, Yusim K, Seaman MS, Yoon H, Theiler J, Giorgi EE, Wagh K, Theiler M, Hraber P, Macke JP, Kreider EF, Learn GH, Hahn BH, Scheid JF, Kovacs JM, Shields JL, Lavine CL, Ghantous F, Rist M, Bayne MG, Neubauer GH, McMahan K, Peng H, Chéneau C, Jones JJ, Zeng J, Ochsenbauer C, Nkolola JP, Stephenson KE, Chen B, Gnanakaran S, Bonsignori M, Williams LD, Haynes BF, Doria-Rose N, Mascola JR, Montefiori DC, Barouch DH*, Korber B*. HIV-1 neutralizing antibody signatures and application to epitope-targeted vaccine design. Cell Host Microbe 2019; 25:59-72.

Zika virus vaccines.

/in

Abbink P, Stephenson KE, Barouch DH. Zika virus vaccines. Nat Rev Microbiol. 2018 Oct;16(10):594-600. doi: 10.1038/s41579-018-0039-7. Review. PubMed PMID: 29921914; PubMed Central PMCID: PMC6162149.

Therapeutic vaccination for HIV: hopes and challenges.

/in

Stephenson KE. Therapeutic vaccination for HIV: hopes and challenges. Curr Opin HIV AIDS. 2018 Sep;13(5):408-415. doi: 10.1097/COH.0000000000000491. Review. PubMed PMID: 29957615.

Similar epitope specificities of IgG and IgA antibodies elicited by Ad26 vector prime, Env protein boost immunizations in rhesus monkeys.

/in ,

Kang ZH, Bricault CA, Borducchi EN, Stephenson KE, Seaman MS, Pau M, Schuitemaker H, van Manen D, Wegmann F, Barouch DH. Similar epitope specificities of IgG and IgA antibodies elicited by Ad26 vector prime, Env protein boost immunizations in rhesus monkeys. J. Virol. 2018; 92:e00537-18.